SNDX Drops 2.41% Despite Nearly Doubled Sales — Here's Why Shares Fell

Syndax Pharmaceuticals (NASDAQ:SNDX) posted second-quarter results that would seem to warrant celebration — nearly doubled revenue driven by its two approved drugs — yet shares slipped 2.41% anyway, leaving traders and analysts to parse the details behind the selloff.

Market Context

The broader pharmaceutical sector has been navigating a complex landscape in recent quarters, with investors increasingly focused on path to profitability and competitive positioning rather than top-line growth alone. Syndax's decline came despite the company reporting combined product sales of $115 million across Revuforj and Niktimvo during the quarter, with both drugs now annualizing above $200 million annually. The S&P 500 pharmaceutical sub-sector has seen mixed trading as market participants weigh pipeline prospects against near-term financial pressures.

Analysis

The stock's decline despite strong revenue growth appears tied to several factors that emerged on the earnings call and in subsequent investor discussions. Revuforj, Syndax's lead menin inhibitor, reported $55 million in net revenue for the quarter — up 91% year-over-year and 12% from the prior quarter — with total prescriptions reaching roughly 1,500, a 15% sequential increase. The drug now sits on formularies covering 98% of insured lives, with preferential access on plans representing 17% of covered lives versus less than 2% for its rival menin inhibitor.

However, management acknowledged fluctuations in new patient starts tied to physicians weighing multiple menin inhibitors depending on a patient's mutation profile — an early signal that competition may shape growth trajectories more than market size alone. Revuforj added approximately 250 new patients during the quarter, and while the drug shows strong staying power with about 50% of KMT2A patients resuming treatment after stem cell transplant (up from roughly 45% previously), investors noted this figure remains below management's target range of 70% to 80%.

Niktimvo contributed $60 million in revenue, up 67% year-over-year, with 60% to 70% of patients remaining on therapy for at least a year. Yet Syndax only records 25% to 30% of partner Incyte's reported Niktimvo sales as collaboration revenue, meaning headline growth figures understate how much the drug must scale before meaningfully contributing to profitability.

The path to profitability remains distant. Syndax guided to approximately $400 million in R&D and SG&A spending for 2026, excluding $50 million in stock-based compensation, against quarterly product revenue of just $115 million. The company ended the quarter with a $575 million cash balance, which includes $244 million raised in June through 2.25% convertible notes — providing runway but also adding dilution concerns.

Institutional investors appeared focused on upcoming catalysts that remain unreported: axatilizumab results in idiopathic pulmonary fibrosis and frontline chronic graft-versus-host disease, along with new NUP98 leukemia data, are all expected in the fourth quarter. The market's reaction suggests traders are pricing in execution risk on pipeline milestones while questioning whether current spending levels can be justified without clearer profitability timelines.

Key Numbers

- Revuforj Q2 net revenue: $55 million (up 91% year-over-year, up 12% sequentially)

- Niktimvo Q2 revenue: $60 million (up 67% year-over-year)

- Total prescriptions for Revuforj: approximately 1,500 (up 15% quarter-over-quarter)

- Formulary coverage: 98% of insured lives with preferential access on plans covering 17% of covered lives

- Patients resuming Revuforj after stem cell transplant: 50% (targeting 70%-80%)

- Niktimvo patient retention at one year: 60% to 70%

- 2026 R&D and SG&A guidance: approximately $400 million, excluding $50 million stock compensation

- Cash balance: $575 million (including $244 million from June convertible note offering)

What to Watch

The fourth quarter will bring critical pipeline catalysts that could shift investor sentiment. Axatilizumab data in IPF and frontline chronic graft-versus-host disease represents significant binary events for the company's development trajectory, while new NUP98 leukemia results may clarify competitive positioning against rival menin inhibitors. Traders should monitor management commentary on patient start trends and whether Revuforj can maintain its formulary advantages as physician competition intensifies. The gap between revenue growth and path to profitability remains the central question for SNDX shares in coming quarters.

The convertible note offering provides approximately two years of runway at current burn rates, but investors will likely demand clearer milestones around when operating expenses peak relative to revenue scaling. Until then, expect elevated volatility around any pipeline readout or competitive developments in the menin inhibitor space.